Research programme: cancer therapeutics - EpiAxis Therapeutics

Drug Profile

Research programme: cancer therapeutics - EpiAxis Therapeutics

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Canberra
  • Class Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Protein kinase C theta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jun 2017 Preclinical trials in Cancer in Australia prior to June 2017 (unspecified route)
  • 21 Jun 2017 EpiAxis Therapeutics plans the phase I Epi-PRIMED trial for Breast cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in Australia (ACTRN12617000943347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top